{"id":"clopidogrel-by-chewing","safety":{"commonSideEffects":[{"rate":"3-10%","effect":"Bleeding"},{"rate":"1-3%","effect":"Thrombocytopenia"},{"rate":"1-3%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the irreversible binding of clopidogrel's active metabolite to the P2Y12 receptor on platelet surfaces, preventing adenosine diphosphate (ADP) from binding and activating the receptor. As a result, platelet activation and aggregation are reduced, which in turn decreases the risk of thrombotic events such as myocardial infarction and stroke.","oneSentence":"Clopidogrel inhibits platelet activation and aggregation by irreversibly inhibiting the P2Y12 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:25.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Acute coronary syndrome"},{"name":"Myocardial infarction"}]},"trialDetails":[{"nctId":"NCT05934799","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2023-06-16","conditions":"Bioequivalence","enrollment":60},{"nctId":"NCT00889044","phase":"PHASE3","title":"Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2009-04","conditions":"Platlet Aggregation, Major Bleeding Outcomes","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"clopidogrel by chewing","genericName":"clopidogrel by chewing","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clopidogrel is a small molecule medication used to study platelet aggregation and major bleeding outcomes in clinical trials. It is available in various forms, including a film-coated tablet and a form that can be chewed, which is being studied in clinical trials for its potential benefits in patients with non-ST elevation myocardial infarction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}